Proteomics

Dataset Information

0

Serine biosynthesis is a metabolic vulnerability in IDH2-driven breast cancer progression


ABSTRACT: Cancer-specific metabolic phenotypes and their vulnerabilities are one among the viable areas of cancer research. We studied the association of breast cancer subtypes with different metabolic phenotypes and identified isocitrate dehydrogenase 2 (IDH2) as a key player in triple negative breast cancer (TNBC) and HER2. Functional assays combined with mass spectrometry-based analyses reveal the oncogenic role of IDH2 in cell proliferation, anchorage-independent growth, glycolysis, mitochondrial respiration and antioxidant defense. Genome-scale metabolic modeling identified PHGDH and PSAT1 as the synthetic dosage lethal (SDL) partners of IDH2. In agreement, CRISPR-Cas9 knockout of PHGDH and PSAT1 showed the essentiality of serine biosynthesis proteins in IDH2-high cells. The clinical significance of the SDL interaction showed patients with IDH2-high/PHGDH-low have better survival than IDH2-high/PHGDH-high. Furthermore, we show the efficacy of PHGDH inhibitors in treating IDH2-high cells in vitro and in in vivo. Altogether, our study creates a new link between two known cancer regulators and emphasizes PHGDH as a promising target for TNBC with IDH2 overexpression.

INSTRUMENT(S): Q Exactive Plus

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Tamar Geiger  

LAB HEAD: Tamar Geiger

PROVIDER: PXD023142 | Pride | 2021-01-04

REPOSITORIES: Pride

Dataset's files

Source:

Similar Datasets

2023-07-20 | PXD017809 | Pride
2010-04-19 | E-GEOD-20085 | biostudies-arrayexpress
2010-04-19 | GSE20085 | GEO
2021-11-04 | GSE144506 | GEO
2022-03-30 | GSE198380 | GEO
2024-02-01 | GSE248632 | GEO
2024-02-01 | GSE248633 | GEO
2015-11-19 | E-GEOD-75130 | biostudies-arrayexpress
2021-09-09 | PXD020585 | Pride
2024-04-23 | GSE173270 | GEO